Edgewise Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Edgewise Therapeutics, Inc. (EWTX) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 49.26 million shares for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-11-10
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 49.26M shares, a 4880.27% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 49.26M shares, a 9152.10% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 1.56M shares, a 270.97% increase year-over-year.
- Edgewise Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 989.20K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month |
|---|---|---|---|
| 2021-09-30 | 49.26M shares 10-Q · filed 2021-11-10 | 49.26M shares derived: average of 2 quarters · filed 2021-11-10 | 33.54M shares 10-Q · filed 2021-11-10 |
| 2021-06-30 | 49.26M shares 10-Q · filed 2021-08-09 | 25.54M shares 10-Q · filed 2021-08-09 | |
| 2021-03-31 | 1.56M shares 10-Q · filed 2021-05-13 | ||
| 2020-09-30 | 989.20K shares 10-Q · filed 2021-11-10 | 760.80K shares derived: average of 2 quarters · filed 2021-11-10 | 648.61K shares 10-Q · filed 2021-11-10 |
| 2020-06-30 | 532.40K shares 10-Q · filed 2021-08-09 | 476.44K shares 10-Q · filed 2021-08-09 | |
| 2020-03-31 | 420.48K shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |